A nurse prepares to administer the AstraZeneca/Oxford vaccine under the COVAX scheme against the coronavirus disease (COVID-19) at the Eka Kotebe General Hospital in Addis Ababa, Ethiopia March 13, 2021. REUTERS FILE PHOTO
BEIJING — China’s Clover Biopharmaceuticals announced on Wednesday an advance purchase agreement to supply up to 414 million doses of its COVID-19 vaccine candidate through the global vaccine sharing scheme COVAX.
The firm said it will supply an initial 64 million doses this year, pending an emergency use listing from the World Health Organization (WHO) of its vaccine candidate.
The Global Alliance for Vaccines and Immunization (GAVI), which leads the COVAX scheme alongside the WHO, has options for an additional 350 million doses in 2022, Clover said.
In exchange for the supply, Clover will receive unspecified upfront payment upon positive Phase II/III trial data on its vaccine candidate.
The candidate entered a global large-scale trial in March and contains an effect-boosting adjuvant provided by Dynavax.